0
Abstract: Poster Presentations |

IS THERE STILL A PLACE FOR GLYCOPROTEIN IIB–IIIA INHIBITORS IN MODERN TREATMENT OF ST-ELEVATION MYOCARDIAL INFARCTION? FREE TO VIEW

Elisabete Jorge; Rui Baptista; Sílvia Monteiro; Rogério Teixeira; Fátima Saraiva; Paulo Mendes; Carolina Lorenço; Pedro Monteiro; Mário Freitas; Luis Augusto Providncia
Author and Funding Information

Coimbra University Hospital and Medical School, Coimbra, Portugal


Chest


Chest. 2009;136(4_MeetingAbstracts):108S-c-109S. doi:10.1378/chest.136.4_MeetingAbstracts.108S-c
Text Size: A A A
Published online

Abstract

PURPOSE:  To determine, in a group of patients admitted with ST-elevation myocardial infarction (STEMI), if those treated with Glicoprotein IIb/IIIa inhibitors (GP IIb/IIIa) in the context of primary percutaneous coronary intervention (PCI) differ from patients who were not, regarding epidemiological profile, clinical presentation and prognosis.

METHODS:  A total of 609 consecutive patients with STEMI were evaluated, admitted in a 3-year period (2004–2007) in a single coronary care unit. All patients were submitted to coronary angiography and 518 underwent primary PCI. This later population was divided in two groups: A - treated with GP IIb/IIIa (n = 248) and B –not medicated with GP IIb/IIIa (n = 270).

RESULTS:  Group A patients were younger (63 vs. 69 years, p < 0.001), had higher levels of necrosis myocardial markers (troponins, CK-MB mass and CK) (p < 0.001), higher creatinin clearance (76.6 vs. 62.8 mL/min; p < 0.001), higher levels of haemoglobin at admission (14.4 vs. 13.7 g/dL; p < 0.001) and higher BMI (28 vs 27 Kg/m2; p < 0.05). Male gender was more likely to receive GP IIb/IIIa (51% vs. 33%, p < 0.001). Prior history of PCI was significantly more frequent in group A (8.5 vs. 1.6%; p < 0.001). Regarding previous medical therapy, patients medicated with GP IIb/IIIa were more frequently taking statins (35.9 vs. 21.4%; p = 0.008). In relation to therapy in the first 24 hours, group A received significantly more aspirin (98.2 vs.94.9%; p = 0.03) and clopidogrel (92.7 vs 57.9%; p < 0.001). There were no significant differences between the two groups regarding family history, hypertension, diabetes, smoking and previous myocardial infarction, stroke and heart failure. GPIIb/IIIa use was protective regarding in-hospital mortality (7.2 vs. 12.1%; p = 0.044), although no significant difference was found between groups regarding 30-day, 180-day and 1-year mortality (6.5% vs. 8.5%, Log-rank p = 0.180).

CONCLUSION:  In our population, GP IIb/IIIa use in the context of primary PCI shown a protective role regarding in-hospital mortality, which was somewhat lost during follow-up.

CLINICAL IMPLICATIONS:  GP IIb/IIIa, associated with stenting, are a mainstay in reperfusion strategy in ST-elevation myocardial infarction (STEMI).

DISCLOSURE:  Elisabete Jorge, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, November 4, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543